Post‐Marketing Requirements for Cancer Drugs Approved by the European Medicines Agency, 2004

Post‐Marketing Requirements for Cancer Drugs Approved by the European Medicines Agency, 2004–2014

Published:2022-06-23 Issue:4 Volume:112 Page:846-852
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin Pharma and Therapeutics

Author:

Cherla Avi¹,Mossialos Elias¹,Salcher‐Konrad Maximilian¹²,Kesselheim Aaron S.³^ORCID,Naci Huseyin¹^ORCID

Affiliation:

1. Department of Health Policy London School of Economics and Political Science London UK

2. Austrian National Public Health Institute (Gesundheit Österreich GmbH/GÖG) Vienna Austria

3. Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Program on Regulation, Therapeutics, and Law (PORTAL) Brigham and Women’s Hospital and Harvard Medical School Boston Massachusetts USA

Funder

London School of Economics and Political Science

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.2679

Reference21 articles.

1. European Medicines Agency.Post‐authorisation measures. Accessed February 16 2021.

2. Generating comparative evidence on new drugs and devices after approval

3. An investigation into drug products withdrawn from the EU market between 2002 and 2011 for safety reasons and the evidence used to support the decision-making

5. Postmarket Safety Events Among Novel Therapeutics Approved by the US Food and Drug Administration Between 2001 and 2010

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessing Post‐Marketing Requirements for Orphan Drugs: A Cross‐Sectional Analysis of FDA and EMA Oversight;Clinical Pharmacology & Therapeutics;2024-08-28

2. Continued cancer drug approvals in Japan and Europe after market withdrawal in the United States: A comparative study of accelerated approvals;Clinical and Translational Science;2024-07

3. A descriptive analysis of postmarketing requirement studies and clinical trials;Pharmacoepidemiology and Drug Safety;2023-11-23

4. Assessment of Surrogate End Point Trends in Clinical Trials to Approve Oncology Drugs From 2001 to 2020 in Japan;JAMA Network Open;2023-04-28

5. Implications of Oncology Trial Design and Uncertainties in Efficacy-Safety Data on Health Technology Assessments;Current Oncology;2022-08-16